semaglutide antidote Receives FDA Approval for Treatment of MASH GLP-1 Medication + Support Plan

What's the legal status of Sermorelin

Trott, O

Neal B, Perkovic V, Mahaffey K, et al

Early preclinical studies report improvements in memory-related tasks and markers of neural plasticity, but clinical evidence and long-term safety data remain limited

Eli Lillys Legal Action Against Compounded Tirzepatide Providers As of October 2024, Lilly filed lawsuits against vendors, medical spas, and pharmacies selling unauthorized compounded GLP-1 products, including Tirzepatide and Mounjaro

[1] In a study published by the New England Journal of Medicine, study participants treated with semaglutide were found to have lost an average of 14.9% of their body weight at week 68, as compared to 2.4% of participants treated with a placebo